The Biologics News and Reports Portal
The Biologics News and Reports Portal STOCKHOLM, MA, 2020 I Swedish Biovitrum AB (publ) (Sobi™) Selecta Biosciences, with randomization of first in study. “We pleased to have commenced phase DISSOLVE program SEL-212 in two phase double-blind,” said Carsten Brunn, of Selecta. “SEL-212 serves an validation of Selecta’s ImmTORTM we look forward to patients in studies continuing to evaluate SEL-212 The Biologics News a new, of Sobi, “SEL-212 has potential to significantly improve for patients with chronic gout. With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone Roots Analysis has announced the addition of the “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings. Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a my...